[go: up one dir, main page]

HK1216502A1 - Trans clomiphene for use in cancer therapy - Google Patents

Trans clomiphene for use in cancer therapy

Info

Publication number
HK1216502A1
HK1216502A1 HK16104449.1A HK16104449A HK1216502A1 HK 1216502 A1 HK1216502 A1 HK 1216502A1 HK 16104449 A HK16104449 A HK 16104449A HK 1216502 A1 HK1216502 A1 HK 1216502A1
Authority
HK
Hong Kong
Prior art keywords
cancer therapy
trans clomiphene
clomiphene
trans
cancer
Prior art date
Application number
HK16104449.1A
Other languages
Chinese (zh)
Inventor
Joseph S Podolski
Ronald D Wiehle
Kuang Hsu
Greg Fontenot
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of HK1216502A1 publication Critical patent/HK1216502A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK16104449.1A 2012-11-02 2016-04-19 Trans clomiphene for use in cancer therapy HK1216502A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261722013P 2012-11-02 2012-11-02
PCT/US2013/066141 WO2014070523A1 (en) 2012-11-02 2013-10-22 Trans-clomiphene for use in cancer therapy

Publications (1)

Publication Number Publication Date
HK1216502A1 true HK1216502A1 (en) 2016-11-18

Family

ID=50627954

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104449.1A HK1216502A1 (en) 2012-11-02 2016-04-19 Trans clomiphene for use in cancer therapy

Country Status (10)

Country Link
US (1) US9687458B2 (en)
EP (1) EP2914294A1 (en)
JP (3) JP2015535283A (en)
CN (1) CN104994877A (en)
AU (1) AU2013338311A1 (en)
CA (1) CA2889770A1 (en)
HK (1) HK1216502A1 (en)
IL (1) IL238453A0 (en)
MX (1) MX2015005160A (en)
WO (1) WO2014070523A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022325A1 (en) * 2014-08-05 2016-02-11 The Penn State Research Foundation Novel triarylethylene compounds and methods using same
CN108348605B (en) 2015-11-10 2023-06-09 帕拉卡林治疗公司 Treatment of ER-negative breast cancer with PDGF-CC inhibitors and antiestrogens
JP2018002619A (en) * 2016-06-29 2018-01-11 国立大学法人 東京大学 Autophagy inhibitor
WO2018058032A1 (en) * 2016-09-26 2018-03-29 Repros Therapeutics Inc. Antiestrogens and/or aromatase inhibitors for use in treating obesity and related symptoms
CN108420806A (en) * 2017-02-15 2018-08-21 武汉华杰世纪生物医药有限公司 Antitumor drug with targeting
WO2019236209A2 (en) * 2018-04-27 2019-12-12 Jin Byung Ju Methods for high-content drug screening

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (en) 1971-03-18 1973-07-10 Richardson Merrell Spa USEFUL COMPOUNDS FOR THE SEPARATION OF GEOMETRIC AND STRUCTURAL OPTICAL ISOMERS AND RELATED SYNTHESIS PROCEDURE
US4061733A (en) 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0206021B1 (en) 1985-06-08 1988-08-10 ASTA Pharma AG Derivatives of 1,1,2,2-tetramethyl-1,2-bis(2-fluoro-4-hydroxyphenyl) ethane
US4820736A (en) 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
EP0660821B1 (en) 1992-09-15 1998-01-21 Merrell Pharmaceuticals Inc. Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
JPH10501814A (en) 1994-06-17 1998-02-17 ユニバーシティ・オブ・ネブラスカ・ボード・オブ・リージェンツ In situ gel-forming delivery vehicles for biological agents and methods of use
DE4435368A1 (en) 1994-09-22 1996-03-28 Schering Ag Use of aromatase inhibitors for the manufacture of a medicament for the treatment of a relative androgen deficiency in men
DE69617245T2 (en) 1995-08-17 2002-07-25 Csir, Pretoria CONTROLLED RELEASE PRODUCTS
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
WO1998018610A1 (en) 1996-10-28 1998-05-07 Lengerich Bernhard H Van Embedding and encapsulation of controlled release particles
KR20010006026A (en) 1997-04-03 2001-01-15 존스 홉킨스 유니버시티 스쿨 오브 메디슨 Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making and using the same
US6653297B1 (en) 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US20040176470A1 (en) 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
KR100944136B1 (en) 1998-07-30 2010-02-24 스톨러 엔터프라이지즈 인코포레이티드 Plant treatment with salicylic acid and organic amines
AU5467799A (en) 1998-08-07 2000-02-28 Liya Chen Estrogen receptor modulators
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TWI281398B (en) 1999-06-11 2007-05-21 Watson Pharmaceuticals Inc Administration of non-oral androgenic steroids to women
CA2321321A1 (en) 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
US20020004065A1 (en) 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
CA2395730A1 (en) 2000-01-28 2001-08-02 Endorecherche, Inc. Selective estrogen receptor modulators in combination with estrogens
BR0111141A (en) 2000-05-26 2003-04-08 Harry Fisch Methods of Treating Androgen Deficiency in Men and Treating Male Menopause Related Disorders in Men
US7067557B2 (en) 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
WO2002013802A2 (en) 2000-08-11 2002-02-21 Wyeth Method of treating estrogen receptor positive carcinoma
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
CA2462081A1 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
WO2002055020A2 (en) 2000-12-11 2002-07-18 Testocreme Llc Topical testosterone formulations and associated methods
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
BR0211067A (en) 2001-07-09 2006-10-31 Zonagen Inc Methods and Materials for the Treatment of Testosterone Deficiency in Men
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
AU2002330031B2 (en) 2001-09-21 2007-07-05 Merck & Co., Inc. Androstanes as androgen receptor modulators
US20060269611A1 (en) 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050042268A1 (en) 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20080242726A1 (en) 2004-07-14 2008-10-02 Podolski Joseph S Trans-Clomiphene for the Treatment of Benign Prostate Hypertrophy, Porstate Cancer, Hypogonadism Elevated Triglycerides and High Cholesterol
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
JP2008530016A (en) 2005-02-04 2008-08-07 リプロス セラピューティクス インコーポレイテッド Methods using trans-clomiphene for the treatment of male infertility and substances containing trans-clomiphene
JP2008537538A (en) 2005-02-11 2008-09-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Therapeutic combination of VEGF antagonist and antihypertensive agent
EP2392322A3 (en) 2005-03-22 2012-02-22 Repros Therapeutics Inc. Dosing regimes for trans-clomiphene
JP2008543855A (en) 2005-06-13 2008-12-04 ライジェル ファーマシューティカルズ, インコーポレイテッド Methods and compositions for treating degenerative bone disease
BRPI0615165A2 (en) 2005-08-05 2016-09-13 Repros Therapeutics Inc infertility treatment method
US7613937B2 (en) 2005-10-31 2009-11-03 Hewlett-Packard Development Company, L.P. Method and apparatus for utilizing a microcontroller to provide an automatic order and timing power and reset sequencer
US7476405B2 (en) 2006-02-23 2009-01-13 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
US20080112888A1 (en) * 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
EP2078376B1 (en) 2007-06-26 2010-12-29 Media Patents, S. L. Router for managing multicast groups
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
EP2826475B1 (en) 2007-10-16 2019-03-20 Repros Therapeutics Inc. Trans-clomiphene for treating diabetes in hypogonadal men
US20100111901A1 (en) 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
TW201500041A (en) 2008-11-07 2015-01-01 Repros Therapeutics Inc Trans-clomiphene for metabolic syndrome and diabetes mellitus type 2
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
UA113291C2 (en) 2011-08-04 2017-01-10 TRANSCLOMYPHENE METABOLITES AND THEIR APPLICATIONS
US20140235601A1 (en) 2011-08-09 2014-08-21 Kenneth W. Adams Use of Aromatase Inhibitor Or Estrogen Blocker For Increasing Spermatogenesis Or Testosterone Levels In Males
EP2819676B1 (en) 2012-02-29 2018-05-30 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
KR20150041793A (en) 2012-08-21 2015-04-17 레프로스 쎄라피우틱스 아이엔씨. Trans-Clomiphene Formulations and Uses Thereof
CN103351304B (en) 2013-07-01 2015-12-09 暨明医药科技(苏州)有限公司 A kind of synthetic method of MRL-41

Also Published As

Publication number Publication date
JP2015535283A (en) 2015-12-10
JP2021046448A (en) 2021-03-25
MX2015005160A (en) 2015-07-17
US9687458B2 (en) 2017-06-27
CN104994877A (en) 2015-10-21
IL238453A0 (en) 2015-06-30
AU2013338311A1 (en) 2015-05-14
US20150283099A1 (en) 2015-10-08
CA2889770A1 (en) 2014-05-08
WO2014070523A1 (en) 2014-05-08
JP2018123168A (en) 2018-08-09
EP2914294A1 (en) 2015-09-09

Similar Documents

Publication Publication Date Title
IL267242B (en) Cancer treatment
HK1213444A1 (en) Cancer treatments
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
HK1252579A1 (en) Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
DK3010519T3 (en) Oncolytic adenovirus for use in a treatment of brain cancer
PL2780332T3 (en) Morpholinylbenzotriazines for use in cancer therapy
HK1216502A1 (en) Trans clomiphene for use in cancer therapy
SG10201702375RA (en) Telomerase inhibitors for use in therapy
GB201218084D0 (en) Novel compounds and methods for use in medicine
HK1210023A1 (en) Cancer treatment
GB201207305D0 (en) Therapy
EP2934500A4 (en) Combination therapy for cancer
GB201106630D0 (en) Cancer therapy
GB201222563D0 (en) Cancer treatment
AU2012900259A0 (en) Agents for use in cancer therapy
IL239231A0 (en) Combination therapy for cancer
GB201214454D0 (en) Therapeutic treatments
GB201214456D0 (en) Therapeutic treatments
GB201223371D0 (en) Novel mucinase for use in therapy or prophylaxis
GB201118220D0 (en) Cancer therapy
GB201211528D0 (en) Therapeutic apparatus